Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123,650,000
-
Total 13F shares
-
123,575,228
-
Share change
-
+844,072
-
Total reported value
-
$2,420,779,402
-
Put/Call ratio
-
39%
-
Price per share
-
$19.59
-
Number of holders
-
206
-
Value change
-
+$15,453,356
-
Number of buys
-
104
-
Number of sells
-
85
Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q1 2018
As of 31 Mar 2018,
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by
206 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
123,575,228 shares.
The largest 10 holders included
Third Security, LLC, VANGUARD GROUP INC, BlackRock Inc., BB BIOTECH AG, IRIDIAN ASSET MANAGEMENT LLC/CT, STATE STREET CORP, Invesco Ltd., JPMORGAN CHASE & CO, First Eagle Investment Management, LLC, and FMR LLC.
This page lists
207
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.